Contacts
Investor Contact
917-362-1370
investor@agenusbio.com
Media Contact
781-674-4784
communications@agenusbio.com
Agenus Inc. (“Agenus”) (Nasdaq:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming B. Riley Virtual Healthcare Conference on January 18th. The fireside chat will take place at 3:00 p.m. ET on January 18th.
To access this event, please RSVP to your B. Riley Securities sales representative. Following the event, a replay of the fireside chat will be posted to the company’s website at https://investor.agenusbio.com/events-and-presentations.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240104722958/en/
Related news for (AGEN)
- France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
- 24/7 Market News Snapshot 09 September, 2025 – Agenus Inc. (NASDAQ:AGEN)
- Today’s Top Performers: MoBot’s Market Review 07/11/25 03:00 PM
- Into the Homestretch: Must-Watch Stocks Heading into After-Hours
- Top Must-Watch Stocks: Disruptive Deals, Strategic Milestones, and Emerging Market Leaders to Watch